Raymond James lowered the firm’s price target on Merit Medical (MMSI) to $83 from $101 and keeps an Outperform rating on the shares. Merit Medical delivered a solid Q1 with a modest revenue beat and strong EPS upside driven by gross margin strength, despite slightly below-trend organic growth due to temporary headwinds, with improving expectations for sequential acceleration through the year reinforcing confidence in the medium-term growth algorithm, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target lowered to $80 from $100 at BofA
- Analyst Reiterates Buy on Merit Medical Systems as Strong Q1 Results and Cash Generation Offset Growth Deceleration, Trims Price Target to $90 on Sector Multiple Compression
- Steed Maintains Hold on Balanced Risk-Reward, Cutting Price Target to $80 Despite Solid Q1 Beat and Slight Guidance Raise
- Merit Medical price target lowered to $85 from $90 at Canaccord
- Merit Medical Earnings Call Highlights Growth Amid Headwinds